These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 15784740)

  • 41. Redirecting
    Gessler DJ; Li D; Xu H; Su Q; Sanmiguel J; Tuncer S; Moore C; King J; Matalon R; Gao G
    JCI Insight; 2017 Feb; 2(3):e90807. PubMed ID: 28194442
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease.
    McPhee SW; Francis J; Janson CG; Serikawa T; Hyland K; Ong EO; Raghavan SS; Freese A; Leone P
    Brain Res Mol Brain Res; 2005 Apr; 135(1-2):112-21. PubMed ID: 15857674
    [TBL] [Abstract][Full Text] [Related]  

  • 43. rAAV Gene Therapy in a Canavan's Disease Mouse Model Reveals Immune Impairments and an Extended Pathology Beyond the Central Nervous System.
    Ahmed SS; Schattgen SA; Frakes AE; Sikoglu EM; Su Q; Li J; Hampton TG; Denninger AR; Kirschner DA; Kaspar B; Matalon R; Gao G
    Mol Ther; 2016 Jun; 24(6):1030-1041. PubMed ID: 27039844
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effects of lithium chloride and other substances on levels of brain N-acetyl-L-aspartic acid in Canavan disease-like rats.
    Baslow MH; Kitada K; Suckow RF; Hungund BL; Serikawa T
    Neurochem Res; 2002 May; 27(5):403-6. PubMed ID: 12064356
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regulation of NAA-synthesis in the human brain in vivo: Canavan's disease, Alzheimer's disease and schizophrenia.
    Harris K; Lin A; Bhattacharya P; Tran T; Wong W; Ross B
    Adv Exp Med Biol; 2006; 576():263-73; discussion 361-3. PubMed ID: 16802718
    [No Abstract]   [Full Text] [Related]  

  • 46. The pathogenesis of, and pharmacological treatment for, Canavan disease.
    Wei H; Moffett JR; Amanat M; Fatemi A; Tsukamoto T; Namboodiri AM; Slusher BS
    Drug Discov Today; 2022 Sep; 27(9):2467-2483. PubMed ID: 35636725
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quantitative measurements with localized 1H MR spectroscopy in children with Canavan's disease.
    Wittsack HJ; Kugel H; Roth B; Heindel W
    J Magn Reson Imaging; 1996; 6(6):889-93. PubMed ID: 8956134
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Canavan disease: clinical features and recent advances in research.
    Hoshino H; Kubota M
    Pediatr Int; 2014 Aug; 56(4):477-83. PubMed ID: 24977939
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Loss of central auditory processing in a mouse model of Canavan disease.
    von Jonquieres G; Froud KE; Klugmann CB; Wong AC; Housley GD; Klugmann M
    PLoS One; 2014; 9(5):e97374. PubMed ID: 24826990
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease.
    Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ
    Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
    Eke GH; Iscan A; Cece H; Calik M
    Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structural modeling of p.V31F variant in the aspartoacylase gene.
    Krishnamoorthy N; Zayed H
    Metab Brain Dis; 2016 Jun; 31(3):723-6. PubMed ID: 26797702
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Myelin lipid abnormalities in the aspartoacylase-deficient tremor rat.
    Wang J; Leone P; Wu G; Francis JS; Li H; Jain MR; Serikawa T; Ledeen RW
    Neurochem Res; 2009 Jan; 34(1):138-48. PubMed ID: 18478328
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Murine aspartoacylase: cloning, expression and comparison with the human enzyme.
    Namboodiri MA; Corigliano-Murphy A; Jiang G; Rollag M; Provencio I
    Brain Res Mol Brain Res; 2000 May; 77(2):285-9. PubMed ID: 10837925
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bimodal occurrence of aspartoacylase in myelin and cytosol of brain.
    Wang J; Matalon R; Bhatia G; Wu G; Li H; Liu T; Lu ZH; Ledeen RW
    J Neurochem; 2007 Apr; 101(2):448-57. PubMed ID: 17254025
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aspartoacylase gene knockout in the mouse: impact on reproduction.
    Surendran S; Szucs S; Tyring SK; Matalon R
    Reprod Toxicol; 2005; 20(2):281-3. PubMed ID: 15907664
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Homozygosity for mutation G212A of the gene for aspartoacylase is associated with atypical form of Canavan's disease.
    Velinov M; Zellers N; Styles J; Wisniewski K
    Clin Genet; 2008 Mar; 73(3):288-9. PubMed ID: 18070137
    [No Abstract]   [Full Text] [Related]  

  • 58. Aspartoacylase gene knockout results in severe vacuolation in the white matter and gray matter of the spinal cord in the mouse.
    Surendran S; Campbell GA; Tyring SK; Matalon R
    Neurobiol Dis; 2005 Mar; 18(2):385-9. PubMed ID: 15686967
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Global CNS gene transfer for a childhood neurogenetic enzyme deficiency: Canavan disease.
    Leone P; Janson CG; McPhee SJ; During MJ
    Curr Opin Mol Ther; 1999 Aug; 1(4):487-92. PubMed ID: 11713764
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in Canavan mice.
    Ahmed SS; Li H; Cao C; Sikoglu EM; Denninger AR; Su Q; Eaton S; Liso Navarro AA; Xie J; Szucs S; Zhang H; Moore C; Kirschner DA; Seyfried TN; Flotte TR; Matalon R; Gao G
    Mol Ther; 2013 Dec; 21(12):2136-47. PubMed ID: 23817205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.